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Abstract. A new direct agglutination test (DAT) for use with urine samples for the diagnosis of visceral leishmaniasis
(VL) has been developed and compared with the conventional DAT with serum samples and our previously reported
enzyme-linked immunosorbent assay (ELISA) with urine samples (urine ELISA). The new DAT, in which anti-human
IgG was used as enhancing antibody, was tested with urine samples from 75 VL patients and 225 non-VL patients and
healthy people. The sensitivity of the new DAT (90.7%), was almost the same as that of the conventional DAT (91.0%)
and the urine ELISA (93.3%). The specificity of the new DAT (96.4%) was nearly identical with that of the urine ELISA
(97.3%). A urine-based DAT has several advantages over the conventional DAT: sample collection is non-invasive and
it can process larger numbers of samples with smaller amounts of antigen.
INTRODUCTION
Visceral leishmaniasis (VL) or kala-azar is a potentially
fatal disease caused by an intracellular protozoan parasite
of the Leishmania donovani complex. It is caused by L. dono-
vani in the Indian subcontinent and eastern Africa, by
L. infantum in the entire Mediterranean area and the Middle
East, and by L. chagasi in the Latin America, although the
latter two species have been shown to be the same by mo-
lecular techniques.1 More than 47 countries are currently af-
fected by leishmaniasis, with at least 200 million people at risk
and approximately 100,000 new cases annually.2 Visceral
leishmaniasis accounts for 75,000 deaths annually.3
For successful control of the disease, efficient and reliable
diagnosis of VL is essential. Demonstration of the causative
parasites in aspirates from lymph nodes, bone marrow, and
the spleen is the most specific diagnosis, and these aspiration
materials resulted in a sensitivity of 56.3%, 67.1%, and 93.3%,
respectively.4 However, the techniques are invasive, painful,
and hazardous and need skilled personnel and equipped hos-
pitals. Moreover, VL is occurring in places where health ser-
vices are poorly developed. Poor socioeconomic conditions
are associated with a higher risk of infection.5
In VL, high antibody levels are observed prior to detection
of parasite specific T cell responses,6 and several serologic
tests, such as the enzyme-linked immunosorbent assay
(ELISA),7–12 the direct agglutination test (DAT),13–16 and
the indirect immunofluorescent antibody test (IFAT),17 have
provided good diagnosis. Among these techniques, the DAT
has been well accepted as a routine serologic test due to its
simplicity and high sensitivity and specificity.18–21 We re-
cently reported an ELISA for use with urine samples (urine
ELISA) for the diagnosis of VL that showed a sensitivity of
95.0% and a specificity of 95.3%.22 An advantage of the urine
ELISA is its ease in collecting samples. Since young children
are often vulnerable to VL infection,20,23 the use of urine will
facilitate field studies. However, the ELISA requires expen-
sive equipment that is often not available at laboratories in
developing countries. We therefore attempted to use urine in
the DAT. As a first step, serum samples were replaced with
urine samples in a conventional DAT system. In the second
step, antibody (goat anti-human IgG) was added to the sys-
tem to improve its sensitivity. The new DAT with enhancing
antibody showed similar sensitivity and specificity when com-
pared with the conventional serum-based DAT.
MATERIALS AND METHODS
Urine and serum samples. Most samples tested in this study
were the same ones used in our previous study.22 Some ad-
ditional samples from VL patients and control groups were
included. Seventy-five urine samples from defined VL pa-
tients, with an average age of 27.4 years, were collected from
different medical college hospitals in Bangladesh. Among the
75 patients, 27 were confirmed parasitologically: Leishman-
Donovan bodies were detected in splenic aspirates of 13 pa-
tients and in bone marrow aspirates of six patients, and pro-
mastigotes were demonstrated in eight patients after inocu-
lation of aspirate materials in Novy, MacNeal, and Nicolle
medium. Of the other 48 clinically confirmed patients, 43
were positive in the conventional DAT and five were positive
in the aldehyde test. During collection of samples, all patients
were in the course of treatment with sodium antimony glu-
conate with the World Health Organization recommended
dose.24 A total of 225 non-VL urine samples were used. Fifty-
nine control samples were taken from apparently healthy in-
dividuals with no history of kala-azar from endemic areas in
Bangladesh (EHC). Sixty-five samples from Japanese healthy
individuals were used as non-endemic controls (NEHC).
Fifty-eight malaria samples collected in Solomon Islands, 13
tuberculosis samples from Bangladesh, and 23 cutaneous
leishmaniasis (CL) samples from Ecuador, and seven samples
from patients with other diseases were also included. The
other diseases category included two amebic liver abscess pa-
tients, two aplastic anemia patients, one aplastic anemia with
nephrotic syndrome patient, one aortic stenosis patient, and
one viral fever patient. Immediately after collection, NaN3
was added to each sample at the final concentration of 0.1%
as a preservative, and the samples were transported to Japan
at ambient temperature and then kept at 4°C. Fifty-six serum
samples from the same group of VL patients were used for
the conventional DAT.
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The participants were first told that these samples would be
carried to Japan for research purposes only, and not for the
diagnosis of their individual disease. All the samples were
then collected with the consent of the participants or their
parents if they were minors. This study was reviewed and
approved by the Ethics Committee of Aichi Medical Univer-
sity School of Medicine and the Ethical Review Committee of
the Bangladesh Medical Research Council.
Conventional DAT with serum samples. The DAT with se-
rum was performed using the commercially available antigen
produced by Koninklijk Instituut voor de Tropen (Amster-
dam, The Netherlands). The test was performed as described
by Harith and others.13 Briefly, 50 L of two-fold serially
diluted serum samples in physiologic saline (0.15 M NaCl)
containing 1% heat-inactivated fetal bovine serum (FBS)
were applied to each well of a V-shaped microtiter plate. The
initial serum dilution was 1:200. The DAT antigen (50 L)
was then added and after two minutes of gentle shaking on a
level surface, the plate was covered with a lid and left over-
night at room temperature. The control wells contained phys-
iologic saline plus 1% heat-inactivated FBS and DAT anti-
gen. The results were judged against a white background. The
end point titer was determined in reference to a clear sharp-
edged blue spot observed in the control wells. Samples with a
titer  1:3,200 were considered positive.13
DAT with urine samples. Parasite and DAT antigen. Leish-
mania donovani strain DD8, isolated from a Bangladeshi pa-
tient, was used.25 Promastigotes were cultured as described
previously.22 The DAT antigen was prepared following the
procedure of Harith and others.13,14 Briefly, the log phase
promastigotes were harvested, washed five times with cold
Locke’s solution, pH 7.4, at 4°C. The pellet was treated with
20 volumes of 0.4% trypsin at 37°C for 45 minutes. The
trypsin was removed by centrifugation, the pellet was washed
five times with cold Locke’s solution, and the treated promas-
tigotes were then fixed overnight with 1% formaldehyde so-
lution at 4°C. Following fixation, the promastigotes were
washed twice with cold saline (0.15 M NaCl, 0.056 M sodium
citrate, pH 7.4). The promastigotes were then stained with
0.1% Coomassie brilliant blue R-250 for 90 minutes, washed
three times with cold saline, and resuspended at a concentra-
tion of 4.5 × 107 promastigotes/mL with citrate saline contain-
ing 0.4% formaldehyde solution. They were stored at 4°C as
DAT antigen. The quality of the antigen was standardized
with the commercially available antigen using a positive stan-
dard serum sample and other VL serum samples.
DAT without enhancing antibody. A V-shaped 96-well mi-
crotiter plate was used. In the first column of the plate, 50 l
of dilution buffer (physiologic saline mixed with 2% volumes
of a casein buffer [1% casein in 0.05 M Tris-HCl, 0.15 M
NaCl, pH 7.6])/well was applied. This column served as a
negative control. In the first row, 50 L of two-fold serially
diluted (with dilution buffer) positive serum, started at a di-
lution of 1:1,000, was applied to each well a as positive stan-
dard to monitor plate-to-plate variations. Fifty microliters of
urine sample was applied without concentration or dilution to
each of the remaining wells. The DAT antigen (50 L) was
then added to each well. After two minutes of gentle shaking
on a level surface, the plate was left overnight at room tem-
perature.
The results were judged visually and scored according to
the agglutination size. Samples that showed a sharp-edged
blue spot identical to the negative control were considered
negative (−). Samples showing a full well-sized agglutination
were scored plus 3 (+++). An agglutination < plus 3 but half
of plus 3 in diameter was scored plus 2 (++). A plus 1 agglu-
tination (+) had the size between (++) and (−). Some (+)
agglutination showed fine granules around the sharp-edged
agglutination.
DAT with enhancing antibody. The type of microtiter plate
and positive standard sera were the same as in the previous
experiment without antibody, except that physiologic saline
instead of dilution buffer was used for the dilution of standard
sera and in the negative control wells. Fifty microliters of
urine sample was applied as in the previous experiment, to
which the same amount of DAT antigen was added. Fifty
microliters of goat anti-human IgG (enhancing antibody)
(Protos Immunoresearch, San Francisco, CA) was then mixed
at various concentrations and times after the addition of an-
tigen. The concentrations and times tested were 1:100, 1:500,
1:1,000, and 1:2,000 dilutions with dilution buffer for 0.5, 10,
and 20 minutes. The mixture was shaken gently for two min-
utes and incubated overnight at room temperature.
Judgment of the agglutination results was done as de-
scribed earlier in this report. Following a series of optimiza-
tion experiment, it was decided that the enhancing antibody
should be diluted 1:500 and mixed immediately after the ad-
dition of antigen.
Urine ELISA. The ELISA with urine samples from VL
patients and non-VL controls was performed as described
elsewhere.22 Briefly, flat-bottomed, 96-well microtiter plates
(MaxiSorp™; Nunc, Roskilde, Denmark) were coated with 5
g/mL (100 L/well) of acetone-treated L. donovani antigen
and incubated overnight at 4°C. After blocking with the
casein buffer for two hours hr at room temperature, 100 L of
urine (1:10 dilution in casein buffer) was added, and the wells
were incubated at 37°C for 1 hr. After four washes with phos-
phate-buffered saline (PBS), pH 7.4 containing 0.05% Tween
20, the plates were incubated with peroxidase-conjugated
goat anti-human IgG (Tago, Camarillo, CA) (1:4,000 dilution
in casein buffer) at 37°C for one hour. The plates were then
washed four times with PBS, 0.05% Tween 20, pH 7.4, incu-
bated with substrate (2,2-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) [ABTS]; Kirkegaard and Perry Laboratories,
Gaithersburg, MD) for one hour at room temperature, and
the optical density was measured at 415 nm and 492 nm as a
reference. Each sample was assayed in duplicate.
Antibody levels were expressed as units estimated from a
standard curve constructed with serially diluted positive sera.
The cut-off point for IgG antibodies to L. donovani was
calculated as the mean plus three standard deviations of log
(1 + unit) values of the NEHC. The anti-logarithmic cutoff
value (9.0 units) in this study is slightly different from that (7.4
units) determined in our previous study; new batches of an-
tigen and a larger number of NEHC might have caused the
difference.
RESULTS
DAT with urine samples. Urine samples of 57 VL and 137
non-VL patients and healthy people were tested with urine-
based DAT without goat anti-human IgG. The assay showed
a sensitivity of 68.4% (39 of 57 VL samples were positive) and
a specificity of 94.1% (129 of 137 non-VL samples were nega-
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tive) (Table 1). Among 39 VL-positive samples, 12 (30.8%)
were graded as plus 3, 14 (35.9%) as plus 2, and 13 (33.3%) as
plus 1. The specificity of this assay with EHC, malaria, tuber-
culosis, and other diseases was 98.3%, 91.4%, 100%, and
71.4%, respectively. Among the false-positive samples, two
malaria and two other diseases (aplastic anemia and aplastic
anemia with nephrotic syndrome) were plus 3, one malaria
was plus 2, and two malaria and one EHC were plus 1.
The addition of enhancing antibody greatly improved the
urine-based DAT. With 75 VL and 225 non-VL samples, it
showed a sensitivity of 90.7% (68 of 75 VL samples were
positive) and a specificity of 96.4% (217 of 225 non-VL sam-
ples were negative) (Table 2). Among 68 VL-positive samples
46 (67.6%) were graded as plus 3, and 11 (16.2%) each as plus
2 or plus 1. Seven of 75 samples became false negative, of
which four samples were collected from parasitologically con-
firmed patients. The specificity of this assay with EHC,
NEHC, malaria, tuberculosis, CL, and other diseases was
96.6%, 100%, 100%, 92.3%, 87.0%, and 71.4%, respectively.
Although the specificity did not improve much with or with-
out the antibody, its addition reduced the degree of false
reactivity, that is, all false-positive samples showed plus 1
agglutination.
DAT with serum samples. The sensitivity of the conven-
tional DAT was studied with serum samples of 56 VL pa-
tients. Due to a lack of samples, the specificity could not be
determined. The assay showed a sensitivity of 91.1% (51 of 56
VL samples were positive).
The urine-based DAT with enhancing antibody was com-
pared with conventional serum-based DAT with 56-paired
urine and serum samples from defined VL cases. There was a
clear positive correlation between serum and urine DAT re-
sults (r  0.6078, P < 0.001, Spearman’s correlation coeffi-
cient by rank test) (Figure 1). Fifty samples were positive and
four samples were negative in both assays (Table 3). Among
the four false-negative samples, three were from parasitologi-
cally confirmed patients. One parasitologically positive and
conventional DAT-positive sample became negative in the
urine-based DAT. One parasitologically positive but conven-
tional DAT-negative sample became positive in the urine-
based DAT.
Urine ELISA. Urine samples of 75 VL patients and 225
non-VL patients and healthy people were tested with the
ELISA using acetone-treated antigen. The test showed a sen-
sitivity of 93.3% (70 of 75 VL samples were positive) and a
specificity of 97.3% (219 of 225 non-VL samples were nega-
tive) (Table 4). The specificity of this assay with EHC,
NEHC, malaria, tuberculosis, CL, and other diseases was
similar to that of the urine-based DAT with enhancing anti-
body.
When we compared the urine-based DAT with enhancing
antibody with the urine ELISA using 75 VL samples, 68 sam-
ples became positive and five samples became negative in
both assays (Table 3). Three of the five false-negative samples
were collected from parasitologically confirmed patients. Two
urine ELISA-positive samples, one of which was parasitologi-
cally positive, became negative in the urine-based DAT. The
antibody units of these two ELISA positive samples were 35.2
units and 11.9 units.
DISCUSSION
The phlebotomine sand flies transmit VL to humans. Soon
after the insect bite, parasites are found in macrophage
phagolysosomes of hosts. Efficient cellular immune responses
to these parasites can alleviate clinical symptoms and result in
cure.26 With insufficient immune responses, however, the pa-
TABLE 1
Sensitivity and specificity of a urine-based direct agglutination test without anti-human IgG*
Agglutination score
Sensitivity† (%) Specificity‡ (%)
VL EHC M TB OD Total
12 0 2 0 2 4
14 0 1 0 0 1
13 1 2 0 0 3
− 18 58 53 13 5 129
Total 39/57 (68.4) 58/59 (98.3) 53/58 (91.4) 13/13 (100) 5/7 (71.4) 129/137 (94.1)
* VL  visceral leishmaniasis; EHC  healthy controls from endemic areas; M  malaria; TB  tuberculosis; OD  other diseases.
† Number of positive/total number of VL samples.
‡ Number of negative/total number of non-VL samples in each category.
TABLE 2
Sensitivity and specificity of a urine-based direct agglutination test with anti-human IgG*
Agglutination score
Sensitivity† (%) Specificity‡ (%)
VL EHC NEHC M TB CL OD Total
+++ 46 0 0 0 0 0 0 0
++ 11 0 0 0 0 0 0 0
+ 11 2 0 0 1 3 2 8
− 7 57 65 58 12 20 5 218
Total 68/75 (90.7) 57/59 (96.6) 65/65 (100) 58/58 (100) 12/13 (92.3) 20/23 (87.0) 5/7 (71.4) 217/225 (96.4)
* VL  visceral leishmaniasis; EHC  healthy controls from endemic areas; NEHC  healthy controls from non-endemic areas; M  malaria; TB  tuberculosis; CL  cutaneous
leishmaniasis; OD  other diseases.
† Number positive/total number of VL samples.
‡ Number negative/total number of non-VL samples in each category.
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tient may die, in many cases, of pancytopenia. The incubation
period generally varies from two to six months, but it may
have much wider range. Visceral leishmaniasis is targeted
for control under the World Health Organization Special Pro-
gram for Research and Training in Tropical Diseases. The
effective control of VL has been hampered due to the lack of
suitable tools for early detection of infection and effective
chemotherapy. Recently, a long-awaited oral drug, miltefos-
ine, has been shown to be very effective for the treatment of
Indian VL.27 In the near future, with the advent of reliable
early diagnosis, patients could be successfully treated with
oral drugs on an outpatient basis.
In this report, we described a urine-based DAT for the
diagnosis of VL cases. A urine-based DAT without enhancing
antibody showed a sensitivity of 68.4% and a specificity of
94.1%. We succeeded in improving the sensitivity and speci-
ficity by adding goat anti-human IgG to the DAT system. The
DAT with enhancing antibody showed a sensitivity of 90.7%
and a specificity of 96.4%. Addition of the antibody probably
strengthened antibody-mediated bindings between antigen
particles and facilitated the agglutination.
When the sensitivities of the urine-based DAT with the
antibody (90.7%), the serum-based conventional DAT
(91.0%), and the urine ELISA (93.3%) were compared, there
was no difference among three methods (P > 0.8, by chi-
square test). Also, there was no difference in the specificities
between the urine-based DAT with the antibody (96.4%) and
the urine ELISA (97.3%) (P > 0.5, by chi-square test). All
three methods showed relatively low specificity with CL and
other diseases. The CL samples might be more cross-reactive
than other non-VL categories due to the parasitologic simi-
larity of the causative agents. Two aplastic anemia samples
were positive. It seems to be important to study these patients
because both aplastic anemia and VL cause pancytopenia.
The conventional serum-based DAT and ELISA have been
evaluated in various studies. The DAT showed a sensitivity of
92.0–96.5% and a specificity of 99.4−100%.15,21,28 In a recent
study in Brazil, the recombinant K39-based ELISA and strip
test showed a sensitivity of 90% and 89% and a specificity of
100% and 98%, respectively.29 These sensitivity and specific-
ity values are consistent with those of our newly developed
urine-based DAT.
In the conventional DAT, serial dilution of serum samples
is necessary to determine the end point titer, which requires a
large volume of antigen for testing a single sample. Seeking
simplicity, Harith and others proposed that a single dilution
of 1:1,600 be used in a mass screening program.14 However
Boeleart and others28 strongly opposed the use of a single,
universal DAT cut-off titer for all purposes. They suggested
that a DAT cut-off titer had to be made in the context of
variable local conditions. In our urine-based DAT with en-
hancing antibody, samples were used without serial dilution.
We can process a larger number of samples in one plate,
which will reduce the amount of antigen, cost, time, and labor/
test. The cost of enhancing antibody is much cheaper than
that of the DAT antigen needed for serial dilution. Moreover,
the use of urine samples has definite advantages in the field
because of non-invasiveness in collecting samples. In the vil-
lage where many people had experienced blood sampling,
urine collection was accepted well or even welcomed.30 An-
other advantage is that this assay system does not require the
electrical equipment needed for the ELISA. Thus, this
method could be a very useful diagnostic tool for VL espe-
cially in the field.
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